Microbot Medical (FRA:CY9D) Beginning Cash Position: €3.40 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CY9D Microbot Medical Inc FRA:CY9D
21 GF Score
Price €1.25
! 3 Warning Signs
View Full Analysis

What is Microbot Medical Beginning Cash Position?

Microbot Medical FRA:CY9D -3.85% 21 Beginning Cash Position is €3.40 Mil as of Jun. 2026. GuruFocus rates FRA:CY9D with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

Microbot Medical's Beginning Cash Position for the quarter that ended in Jun. 2026 was €3.40 Mil.

Microbot Medical's quarterly Beginning Cash Position declined from Dec. 2025 (€5.77 Mil) to Mar. 2026 (€3.44 Mil) and declined from Mar. 2026 (€3.44 Mil) to Jun. 2026 (€3.40 Mil).

Microbot Medical's annual Beginning Cash Position increased from Dec. 2023 (€2.31 Mil) to Dec. 2024 (€2.40 Mil) and increased from Dec. 2024 (€2.40 Mil) to Dec. 2025 (€2.70 Mil).

Microbot Medical Beginning Cash Position Related Terms

Microbot Medical Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Microbot Medical's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microbot Medical Beginning Cash Position Chart

Microbot Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.46 12.82 2.31 2.40 2.70

Microbot Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.83 3.52 5.77 3.44 3.40
FRA:CY9D
21GF Score
Microbot Medical Inc FRA:CY9D
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Microbot Medical Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €3.40 Mil mean?
Microbot Medical (FRA:CY9D) has a Beginning Cash Position of €3.40 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Microbot Medical and its competitors.
Is Microbot Medical's Beginning Cash Position too high?
Microbot Medical's current Beginning Cash Position is €3.40 Mil. Overall, Microbot Medical has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Microbot Medical's Beginning Cash Position compare to STXS and DXR?
Microbot Medical's Beginning Cash Position of €3.40 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Microbot Medical and its competitors. Microbot Medical's current Beginning Cash Position is €3.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbot Medical stock overvalued right now?
Microbot Medical (FRA:CY9D) has a current Beginning Cash Position of €3.40 Mil. The current Beginning Cash Position is €3.40 Mil. Microbot Medical's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Microbot Medical (FRA:CY9D), the current Beginning Cash Position is €3.40 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microbot Medical Business Description

Other Exchanges MBOT:USA
Address 175 Derby Street, Building 27, Hingham, MA, USA, 02043
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
21GF Score

Get the complete analysis for FRA:CY9D

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.25
Price